Alvotech announced that Faysal Kalmoua has been appointed as Chief Operating Officer and Hafrun Fridriksdottir is stepping down following resubmission of the Biologics License Application (BLA) for AVT02, Alvotech?s proposed high-concentration interchangeable biosimilar to Humira® (adalimumab). Faysal has served as Head of Portfolio and Project Management since earlier this year and as a member of Alvotech?s Board of Directors since 2020. Previously, he held various senior management positions at Alvogen and Synthon.

He has a master?s degree in Chemistry from Radboud University Nijmegen and an executive MBA from Insead.